Omixon at the EFI Annual Meeting 2016

26/04/2016

Omixon announce today that Holotype HLA™ and other Omixon products will be featured in six poster presentations produced by Holotype customers at the annual meeting of the European Federation for Immunogenetics (EFI) on Kos, in Greece. Additionally, Omixon’s Lunch Symposium on Thursday will focus on the EFI accreditation process for NGS...

Holotype HLA Now CE-IVD in Europe

06/04/2016

Omixon announce today that Holotype HLA™ has been approved as a CE Marked IVD for sale in Europe, and will be available from April 2016 to all European customers as IVD, while remains RUO in the USA. Holotype HLA is the most globally recognized Next Generation Sequencing (NGS) Assay...

Omixon Announce Dimitri Monos as Chair of its Scientific Advisory Board

25/02/2016

Omixon announced today that Dr. Dimitri Monos, Director of the Immunogenetics Laboratory of The Children’s Hospital of Philadelphia (CHOP) and Professor of Pathology and Laboratory Medicine at Perelman School of Medicine of the University of Pennsylvania, will join their team as Chair of the company’s Scientific Advisory Board. Professor...

Omixon Announce French Tender Victory

27/01/2016

Omixon today announce that their flagship Holotype HLA assay and software solution for HLA typing by Next Generation Sequencing (NGS) has been selected as the HLA typing solution of choice by the Etablissement Français du Sang (the French National Blood Service, EFS). Omixon won a two-year competitive tender worth...

2015 – A Successful Year in Blogposts

16/12/2015

For Omixon, 2015 was an exciting and successful year with a lot of events, news, travels. We closed the Early Access Program and presented full results at the annual ASHI meeting in Savannah where we held Basic and Advanced workshops on Holotype HLA, and had a fully packed Symposium....